Dr. Michael Carney, MD
Claim this profileKapiolani Medical Center for Women and Children
Expert in Ovarian Cancer
Studies Gastroesophageal Junction Adenocarcinoma
14 reported clinical trials
29 drugs studied
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
BRCA1 positive
Stage III
2Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Michael Carney, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Michael Carney, MD
Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Michael Carney, MD has experience with
- Paclitaxel
- Carboplatin
- Mirvetuximab Soravtansine
- Bevacizumab
- Pembrolizumab
- Olaparib
Breakdown of trials Michael Carney, MD has run
Ovarian Cancer
Gastroesophageal Junction Adenocarcinoma
Skin Cancer
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Carney, MD specialize in?
Michael Carney, MD focuses on Ovarian Cancer and Gastroesophageal Junction Adenocarcinoma. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Michael Carney, MD currently recruiting for clinical trials?
Yes, Michael Carney, MD is currently recruiting for 5 clinical trials in Honolulu Hawaii. If you're interested in participating, you should apply.
Are there any treatments that Michael Carney, MD has studied deeply?
Yes, Michael Carney, MD has studied treatments such as Paclitaxel, Carboplatin, Mirvetuximab Soravtansine.
What is the best way to schedule an appointment with Michael Carney, MD?
Apply for one of the trials that Michael Carney, MD is conducting.
What is the office address of Michael Carney, MD?
The office of Michael Carney, MD is located at: Kapiolani Medical Center for Women and Children, Honolulu, Hawaii 96826 United States. This is the address for their practice at the Kapiolani Medical Center for Women and Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.